New Report Finds States Must Do More to Ensure People at High Risk Can Be Screened for Lung Cancer
American Lung Association, MD Anderson partnership seeks to ensure access to screening for those at high risk for lung cancer through state Medicaid programs
(March 19, 2019) - CHICAGO
For more information please contact:
Lung cancer is the leading cancer killer, yet coverage of screenings for individuals at high risk for lung cancer varies across state Medicaid programs, according to a new report released today by the American Lung Association. To ensure those eligible can access lifesaving lung cancer screenings, the American Lung Association and The University of Texas MD Anderson Cancer Center have partnered on educational initiatives to improve coverage for recommended low-dose computed tomography (CT) lung cancer screenings in state Medicaid programs.
According to the report, "Lung Cancer Screening Coverage in State Medicaid Programs," 31 Medicaid fee-for-service programs cover lung cancer screening, 12 programs do not provide coverage, and 8 states did not have information available on their coverage policy. The analysis also found that Medicaid programs varied in the eligibility criteria they used for screening as well as whether they required prior authorization.
"Lung cancer is called the quiet killer, as it has few early symptoms and is oftentimes caught too late," said American Lung Association President and CEO Harold Wimmer. "Coverage for screening with low-dose CT is critical, and this analysis will advance our work to ensure those eligible with state Medicaid coverage have access to this lifesaving screening."
"Our mission at MD Anderson is to end cancer, and we know that the best way to do this is through cancer prevention and early detection," said Peter WT Pisters, M.D., president of MD Anderson. "Evidence-based screening is vital for those at high risk to ensure that lung cancer, when it's present, is detected as early as possible. These actions must also complement our efforts in tobacco prevention and cessation, through which we could eliminate the vast majority of lung cancers."
Lung cancer screenings can dramatically reduce the mortality from lung cancer in those considered at high risk, and have been recommended by the U.S. Preventive Services Task Force (USPSTF). While screening is covered as a preventive service at no cost by most private health insurance as well as by Medicare, state Medicaid programs are not required to cover the screening or can offer coverage with significant barriers. Coverage for those covered by Medicaid is especially important as 26.3 percent of Medicaid beneficiaries are current smokers—a key factor in being high risk for lung cancer.
The USPSTF defines those at high risk of lung cancer as individuals age 55-80, who have a 30 pack-year history of smoking and currently smoke or have quit smoking within the past 15 years. Eight million Americans are considered at high risk and eligible for this annual screening, and if all those eligible were screened, an estimated 25,000 lives would be saved.
The report also found that state Medicaid programs differ with the eligibility criteria that they use for screening, with 16 states following the USPSTF or very similar Medicare criteria, and 15 states adopting other criteria.
In addition to the analysis released today, the Lung Association and MD Anderson have also released a new toolkit with resources to educate state-level decisionmakers and build awareness among healthcare professionals about gaps in Medicaid coverage of lung cancer screening.
The partnership is supported by MD Anderson's EndTobacco® program, an initiative of the cancer prevention and control platform working to eliminate the substantial burdens of tobacco use. The effort is the result of extensive collaboration between the platform and the Lung Cancer Moon Shot™, which seeks to develop innovative screening and treatment approaches to save lives from lung cancer. All are part of MD Anderson's Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients' lives.
For media interested in scheduling an interview with an expert about lung cancer, screening or healthcare coverage of the test, contact Allison MacMunn with the American Lung Association at [email protected] or 312-801-7628 or Clayton Boldt with MD Anderson at [email protected] or 713-792-9518.
About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to improve the air we breathe; to reduce the burden of lung disease on individuals and their families; and to eliminate tobacco use and tobacco-related diseases. For more information about the American Lung Association, a holder of the coveted 4-star rating from Charity Navigator and a Gold-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 49 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 14 times in the last 17 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.